Given our findings and the increasing role of immunotherapy in the management of high-risk neuroblastoma, it is imperative that ongoing and future clinical trials of both standard of care and novel immunotherapy agents evaluate whether ATRX status is a biomarker of clinical response to these agents. This evidence concerns the gene ATRX and neuroblastoma.